Herrmann K L, Halstead S B, Wiebenga N H
JAMA. 1982 Jan 8;247(2):193-6.
A comparative field trial of three live, attenuated rubella virus vaccines (Cendehill, HPV 77 DE-5, and HPV-77 DK-12) was initiated in 1969 on the islands of Kauai and Hawaii in the state of Hawaii. Following initial seroconversion rates of more than 98%, periodic serological testing of the study population was conducted to assess the durability of vaccine-induced immunity. In February 1980, ten years after the initiation of the study, 741 of the 5,153 original susceptible vaccinees were still enrolled in the study. After a drop of approximately 50% in mean hemagglutination-inhibition (HI) titer for each of the vaccine groups during the first four years following vaccination, the HI titer levels for all three groups have been generally stable between years 4 and 10. The frequency of reversion to an HI titer of less than 10 has remained less than 0.5% per year. A measurable HI antibody level has persisted in more than 97% of all vaccines over the ten-year period. This study indicates that when potent rubella vaccine is administered properly, a high seroconversion rate and a high rate of antibody persistence should be expected.
1969年，在夏威夷州的考艾岛和夏威夷岛上开展了一项针对三种减毒活风疹病毒疫苗（森德希尔疫苗、HPV 77 DE - 5疫苗和HPV - 77 DK - 12疫苗）的比较性现场试验。在初始血清转化率超过98%之后，对研究人群进行了定期血清学检测，以评估疫苗诱导免疫的持久性。1980年2月，即研究开始十年后，5153名最初的易感疫苗接种者中有741人仍参与该研究。在接种疫苗后的头四年里，每个疫苗组的平均血凝抑制（HI）效价下降了约50%，之后在第4年至第10年期间，所有三组的HI效价水平总体保持稳定。HI效价恢复到低于10的频率每年仍低于0.5%。在十年期间，超过97%的所有疫苗接种者都持续保持着可检测到的HI抗体水平。这项研究表明，当正确接种高效风疹疫苗时，应预期会有高血清转化率和高抗体持久性。
